It is one day after the House Energy and Commerce Committee sent a declination letter to the four Congressmen that had been requesting a further review of the questionable FDA ruling for Dendreon’s (DNDN) Provenge, the company’s groundbreaking Prostate cancer drug. Now, a news release shows another beneficial study result...
Tag: prostate cancer
DHUnplugged #379: Slow GrindOct 18, 2017
DHUnplugged #378: The Best Stock Market in The WorldOct 11, 2017
DHUnnplugged #377: We Have FrameworkOct 04, 2017
DHUnplugged #376: Jumpy, Sloppy, TweetySep 27, 2017
DHUnplugged #375: A Breach Of ConfidenceSep 20, 2017